Yuval: ‘I’m glad I took part in the study’
At the beginning of 2025, the Dutch Yuval (21) was diagnosed with Crohn’s disease. She was suffering from frequent diarrhoea, abdominal pain and fatigue. She also lost a lot of weight. She was prescribed medication, but it did not help enough.
“Unfortunately, the medication didn’t work for me. After three months, I still hadn’t noticed any improvement. It just made me sleep very badly.”
Taking part in OmiCrohn
Yuval was asked if she would like to take part in the OmiCrohn study. She decided to participate in the control group. This means that her gastroenterologist chose her medication. In the other study group, artificial intelligence (AI) helps to select the medication that is most likely to work best.
The right medication
Before the study started, Yuval had an endoscopy. Blood samples were also taken, and she had to provide a stool sample. Her gastroenterologist then chose to treat her with ustekinumab.
After six months, Yuval had another endoscopy and further blood tests.
“The medication is working well. My blood results are good and my bowel looks healthy. I’m really happy that my gastroenterologist chose the right medication for me and that I took part in the study. I am curious, though, whether AI would have chosen the same medication for me. Especially now that I know it works for me.”
“I would definitely recommend taking part in the study to others. The extra attention and care you receive during the study is really reassuring.”